We are live on ! Find out more
RETA

Reata Pharmaceuticals, Inc. Class A Common Stock
RETA

Delisted

RETA was delisted on the 25th of September, 2023.

Back to rankings

2 hedge funds and large institutions have $2.98M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 210 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% less call options, than puts

Call options by funds: $16.5M | Put options by funds: $50.7M

99% less funds holding

Funds holding: 214 → 2 (-212)

100% less capital invested

Capital invested by funds: $3.21B → $2.98M (-$3.21B)

100% less funds holding in top 10

Funds holding in top 10: 8 → 0 (-8)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 210

Holders
2
Holders Change
-212
Holders Change %
-99.07%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
210
Calls
$16.5M
Puts
$50.7M
Net Calls
-$34.3M
Net Calls Change
-$53.4M

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
CI
CPMG Inc
Texas
-$295M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$288M
3
BlackRock
BlackRock
New York
-$259M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$180M
5
Deutsche Bank
Deutsche Bank
Germany
-$152M
Name Holding Trade Value Shares
Change 		Change in
Stake
EA
26
Emerald Advisers
Pennsylvania
– -$32.3M -317,096 Closed
Voloridge Investment Management
27
Voloridge Investment Management
Florida
– -$31.7M -311,358 Closed
Fidelity Investments
28
Fidelity Investments
Massachusetts
– -$31.1M -305,225 Closed
T. Rowe Price Associates
29
T. Rowe Price Associates
Maryland
– -$30.2M -295,741 Closed
Northern Trust
30
Northern Trust
Illinois
– -$29.4M -287,968 Closed
EMFAT
31
Emerald Mutual Fund Advisers Trust
Pennsylvania
– -$26M -255,387 Closed
MB
32
MPM BioImpact
Massachusetts
– -$23.9M -234,478 Closed
Goldman Sachs
33
Goldman Sachs
New York
– -$22.2M -218,143 Closed
Charles Schwab
34
Charles Schwab
California
– -$22M -216,012 Closed
Victory Capital Management
35
Victory Capital Management
Texas
– -$21.6M -211,931 Closed
JP Morgan Chase
36
JP Morgan Chase
New York
– -$21M -206,223 Closed
WP
37
Woodline Partners
California
– -$20.9M -205,108 Closed
BSA
38
Braun Stacey Associates
New York
– -$16.8M -164,775 Closed
Morgan Stanley
39
Morgan Stanley
New York
– -$16.6M -162,905 Closed
Norges Bank
40
Norges Bank
Norway
– -$14.8M -145,582 Closed
PHS
41
PFM Health Sciences
California
– -$14.8M -145,147 Closed
Bank of New York Mellon
42
Bank of New York Mellon
New York
– -$13.5M -132,343 Closed
AllianceBernstein
43
AllianceBernstein
Tennessee
– -$13.4M -131,235 Closed
Ensign Peak Advisors
44
Ensign Peak Advisors
Utah
– -$12.9M -126,625 Closed
IHAM
45
Integral Health Asset Management
New York
– -$12.2M -120,000 Closed
SSA
46
Schonfeld Strategic Advisors
New York
– -$11.7M -114,520 Closed
Two Sigma Investments
47
Two Sigma Investments
New York
– -$11.1M -109,131 Closed
SCM
48
Suvretta Capital Management
New York
– -$11.1M -108,832 Closed
ABG
49
Ally Bridge Group
New York
– -$10.8M -105,558 Closed
FLSM
50
Frazier Life Sciences Management
California
– -$10.2M -100,430 Closed
1
2
3 4 5

RETA Hedge Fund Activity: Q3 2023 in Review

2 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q3 2023, worth a combined $2.98M — down 100% from $3.21B a quarter earlier.

Sellers outnumbered buyers: 210 funds closed out of RETA and 0 opened new positions — a net loss of 210 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was CPMG Inc, exiting entirely with an estimated $295M sold.

  • 2 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q3 2023, down from 214 in Q2 2023.
  • Funds reported $2.98M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q3 2023 and 210 closed out, a net change of -210 holders.
  • The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q3 2023 was CPMG Inc, an estimated $295M sold.

Based on aggregated 13F filings for Q3 2023.